# Cilengitide and Metronomic Temozolomide for Relapsed or Refractory High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas in Children and Adolescents

> **NCT01517776** · PHASE2 · TERMINATED · sponsor: **Martin-Luther-Universität Halle-Wittenberg** · enrollment: 28 (actual)

## Conditions studied

- Gliomas

## Interventions

- **DRUG:** Cilengitide
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT01517776
- **Lead sponsor:** Martin-Luther-Universität Halle-Wittenberg
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-01
- **Primary completion:** 2014-03
- **Final completion:** 2014-04
- **Target enrollment:** 28 (ACTUAL)
- **Why stopped:** due to an altered benefit/risk assessment.
- **Last updated:** 2015-07-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01517776

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01517776, "Cilengitide and Metronomic Temozolomide for Relapsed or Refractory High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas in Children and Adolescents". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01517776. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*